This Bill Replaced with a Substitute Bill - Check Primary Bill - HB 2817 - 02/26/2026 - HCS Reported Do Pass (H)
Summary
The bill creates a program that funds and monitors clinical drug trials of ibogaine for opioid use disorder and other neurological conditions, requiring matching private funds and collaboration with out‑of‑state consortia. It also restricts ibogaine prescribing to doctors licensed under chapter 334 who must administer the drug in a hospital or other licensed health‑care facility. The goal is to develop new treatment options for veterans and other at‑risk Missourians.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Topics
Track this bill
Get real-time alerts when HB 2961 changes status, plus AI-powered summaries and stage predictions.
Sign up free